Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2013
10/17/2013US20130272992 Ion binding polymers and uses thereof
10/17/2013US20130272991 Ion binding polymers and uses thereof
10/17/2013US20130272990 Ion binding polymers and uses thereof
10/17/2013US20130272974 Hydroxytyrosol Product, Method of Making, and Uses Thereof
10/17/2013US20130272972 Oral Care Compositions Comprising a Quinone and a Further Antimicrobial Agent
10/17/2013US20130272969 Injectable Cross-Linked Polymeric Preparations and Uses Thereof
10/17/2013US20130272963 Cholesterol Efflux Assay Probe Formulations, Methods of Making and Using
10/17/2013DE102012007558A1 Use of diarylurea-derivatives for treating the symptoms of anemia, thalassemia, sickle cell anemia and Diamond-Blackfan anemia
10/17/2013DE102012007212A1 Zubereitung zur topischen Anwendung auf Schleimhäuten mit Polyhexanid als Wirkstoff Preparation for topical application to mucous membranes with polyhexanide as an active ingredient
10/17/2013CA2809473A1 Stabilized ketorolac compositions
10/16/2013EP2650382A1 Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
10/16/2013EP2650381A1 Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
10/16/2013EP2650380A1 Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
10/16/2013EP2650379A1 Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
10/16/2013EP2650378A1 Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
10/16/2013EP2650369A1 Novel synthetic agonists of TLR9
10/16/2013EP2650299A1 Crystalline salts of sitagliptin
10/16/2013EP2650298A1 Crystalline salts of sitagliptin
10/16/2013EP2650297A1 Crystalline salts of sitagliptin
10/16/2013EP2650296A1 Crystalline salts of sitagliptin
10/16/2013EP2650295A1 Alpha helix mimetics and methods relating thereto
10/16/2013EP2650294A1 Inhibitors of Bruton's Tyrosine Kinase
10/16/2013EP2650293A1 [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof
10/16/2013EP2650292A1 Thiazolamine derivative and use thereof as anti-picornaviral infection medicament
10/16/2013EP2650291A1 Crystalline Antifungal Compounds
10/16/2013EP2650289A1 Glycomimetics as pseudomonas Aeruginosa lectin inhibitors
10/16/2013EP2650288A1 Sleep-improving agent
10/16/2013EP2650287A1 Thiazole Derivative and use thereof as VAP-1 Inhibitor
10/16/2013EP2650286A1 Quinazoline derivatives and therapeutic use thereof
10/16/2013EP2650284A1 Heterocyclic derivatives as metabotropic glutamate receptor modulators
10/16/2013EP2650279A2 Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
10/16/2013EP2650021A1 Medical device for controlled release of drug
10/16/2013EP2650019A1 Noradrenergic and specific serotonergic antidepressant-containing transdermal patch
10/16/2013EP2650016A1 Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
10/16/2013EP2650011A1 Method of treatment or prophylaxis
10/16/2013EP2650010A1 Method of treatment or prophylaxis
10/16/2013EP2650000A1 Utilization of copper complexes involving 2-phenyl-3-hydroxy-4(1H)-quinolinone and 1,10-phenanthroline derivatives for the preparation of drugs for the treatment of tumour diseases
10/16/2013EP2649999A1 Use of quinazoline compound in preparation of anti-flavivirus drug
10/16/2013EP2649998A1 Prolyl hydroxylase inhibitors
10/16/2013EP2649997A1 (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of antecedent hematologic disorders
10/16/2013EP2649996A1 Crystalline forms of sartans like telmisartan with beta blockers
10/16/2013EP2649995A2 Inhibition of post-radiation tumor growth
10/16/2013EP2649994A1 Combinations of aromatase inhibitors and antioxidants
10/16/2013EP2649993A1 Stabilizer of acetaminophen
10/16/2013EP2649992A1 New pharmaceutic use of benzoic aicd derivatives
10/16/2013EP2649991A1 Extracts and isolated compounds from Euphorbia granulata Forrsk. for treatment of ulcerative colitis
10/16/2013EP2649989A1 Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
10/16/2013EP2649988A1 Sustained release of antiinfective aminoglycosides
10/16/2013EP2649453A1 Use of dronedarone for the preparation of a drug for use in the management of the risk of liver injury
10/16/2013EP2649183A1 Bispecific aptamers mediating tumour cell lysis
10/16/2013EP2649099A2 Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
10/16/2013EP2649085A1 Glycomimetic compounds as anti-infectious against pathogens lectins
10/16/2013EP2649084A1 Novel derivatives of oxazaphosphorines that are pre-activated, use and method of preparation
10/16/2013EP2649078A1 4-aza-2, 3-didehydropodophyllotoxin compounds and process for the preparation thereof
10/16/2013EP2649077A1 Hiv integrase inhibitors
10/16/2013EP2649076A1 Macrocyclic inhibitors of flaviviridae viruses
10/16/2013EP2649075A1 Substituted pyrazolopyrimidines as glucocerebrosidase activators
10/16/2013EP2649074A1 Hiv integrase inhibitors
10/16/2013EP2649072A1 Imidazo [1, 2-a]pyridine sulfonamides as trpm8 modulators
10/16/2013EP2649071A1 Imidazo(4,5-b)pyridine-6-carboxamides as anti-inflammatory agents
10/16/2013EP2649070A1 Triazolopyridine compounds
10/16/2013EP2649069A1 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
10/16/2013EP2649068A1 Oxazolyl-methylether derivatives as alx receptor agonists
10/16/2013EP2649067A1 Benzofurane derivatives for the treatment of hepatitits c
10/16/2013EP2649066A1 Hydantoin derivatives useful as kv3 inhibitors
10/16/2013EP2649065A1 Bicyclic compounds as pim inhibitors
10/16/2013EP2649064A1 Novel triazole compounds iii
10/16/2013EP2649063A1 Triazole derivatives as wnt signaling pathway inhibitors
10/16/2013EP2649062A1 Bicyclic compounds as inhibitors of acetyl-coa carboxylase (acc)
10/16/2013EP2649061A1 Pyridine amide derivatives as ep4 receptor antagonists
10/16/2013EP2649060A2 Process for the preparation of benzimidazole derivatives and its salts
10/16/2013EP2649052A1 2 -aminobenz imidazole derivatives useful in the treatment of inflammation
10/16/2013EP2649051A1 6-amino-2-phenylamino-1h-benzimidazole-5-carboxamide- derivatives and their use as microsomal prostaglandin e2 synthase-1 inhibitors
10/16/2013EP2649050A1 Compounds
10/16/2013EP2649048A1 Multifunctional nitroxide derivatives and uses thereof
10/16/2013EP2649047A1 Process for the manufacture of ajoene derivatives
10/16/2013EP2649046A1 [((1r,2s,5r)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester and related compounds and their use in therapy
10/16/2013EP2649035A1 A complex of garcinol, cyclodextrin and method thereof
10/16/2013EP2649033A2 Compositions and methods for stabilizing ingredients using 2,4-pentanedione compounds
10/16/2013EP2648817A1 Method of extracting active molecules from natural resins and use thereof
10/16/2013EP2648807A1 Combination preparation for improving female fertility
10/16/2013EP2648762A2 Post-treatment breast cancer prognosis
10/16/2013EP2648760A2 Smart polymeric nanoparticles which overcome multidrug resistance to cancer chemotherapeutics and treatment-related systemic toxicity
10/16/2013EP2648756A2 Targeting kidney mesangium with nanoparticles of defined diameter
10/16/2013EP2648754A2 Methods of inhibiting metastasis from cancer
10/16/2013EP2648738A2 Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents
10/16/2013EP2648737A1 Treating conditions associated with increased eotaxin with 25-hydroxyvitamin d3
10/16/2013EP2648736A2 Cycloalkyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
10/16/2013EP2648735A2 Granzyme b inhibitor compositions, methods and uses for promoting wound healing
10/16/2013EP2648734A1 Methods of metabolic targeting cancer cells using che mo- and immunotherapy for treating cancer
10/16/2013EP2648733A1 Substituted imidazoquinoline derivatives
10/16/2013EP2648732A1 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
10/16/2013EP2648731A1 Carboxamide compounds and their use as calpain inhibitors v
10/16/2013EP2648730A2 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
10/16/2013EP2648729A1 Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer
10/16/2013EP2648728A2 Janus kinase 2 (jak2) inhibitor for the treatment of lupus
10/16/2013EP2648727A2 Compositions and methods for mobilizing stem cells
10/16/2013EP2648726A1 Polycyclic lpa1 antagonist and uses thereof
10/16/2013EP2648725A1 TREATMENT OF CHRONIC INFLAMMATION WITH A 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVE
10/16/2013EP2648724A1 Hydroxylated aminotriazole derivatives as alx receptor agonists
1 ... 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 ... 7860